151 related articles for article (PubMed ID: 30114867)
1. Human papillomavirus vaccination update: Nonavalent vaccine and the two-dose schedule.
Brotherton JM
Aust J Gen Pract; 2018 Jul; 47(7):417-421. PubMed ID: 30114867
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
[TBL] [Abstract][Full Text] [Related]
3. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
Patel C; Brotherton JM; Pillsbury A; Jayasinghe S; Donovan B; Macartney K; Marshall H
Euro Surveill; 2018 Oct; 23(41):. PubMed ID: 30326995
[TBL] [Abstract][Full Text] [Related]
4. The Clinical and Economic Impact of a Nonavalent Versus Bivalent Human Papillomavirus National Vaccination Program in Taiwan.
Chou HH; Chang SC; Sukarom I; Saxena K; Pavelyev A; Wu YH; Chang CJ
Value Health Reg Issues; 2022 Nov; 32():79-87. PubMed ID: 36116338
[TBL] [Abstract][Full Text] [Related]
5. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
6. Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines.
Van Damme P; Bonanni P; Bosch FX; Joura E; Kjaer SK; Meijer CJ; Petry KU; Soubeyrand B; Verstraeten T; Stanley M
Vaccine; 2016 Feb; 34(6):757-61. PubMed ID: 26772631
[TBL] [Abstract][Full Text] [Related]
7. The projected timeframe until cervical cancer elimination in Australia: a modelling study.
Hall MT; Simms KT; Lew JB; Smith MA; Brotherton JM; Saville M; Frazer IH; Canfell K
Lancet Public Health; 2019 Jan; 4(1):e19-e27. PubMed ID: 30291040
[TBL] [Abstract][Full Text] [Related]
8. [Human papillomavirus nonavalent vaccine. Update 2017].
Bosch FX; Moreno D; Redondo E; Torné A
Semergen; 2017; 43(4):265-276. PubMed ID: 28549940
[TBL] [Abstract][Full Text] [Related]
9. Vaccination against HPV and view of new possibilities.
Mladěnka A; Sláma J
Ceska Gynekol; 2018; 83(3):218-225. PubMed ID: 30764623
[TBL] [Abstract][Full Text] [Related]
10. Potential impact of introducing a nonavalent HPV vaccination.
Bogani G; Taverna F; Lombardo C; Signorelli M; Chiappa V; Casarin J; Scaffa C; Leone Roberti Maggiore U; Recalcati D; Ditto A; Martinelli F; Borghi C; Perotto S; Ferrero S; Lorusso D; Raspagliesi F
Int J Gynaecol Obstet; 2018 Sep; 142(3):338-342. PubMed ID: 29858884
[TBL] [Abstract][Full Text] [Related]
11. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.
Herweijer E; Leval A; Ploner A; Eloranta S; Simard JF; Dillner J; Netterlid E; Sparén P; Arnheim-Dahlström L
JAMA; 2014 Feb; 311(6):597-603. PubMed ID: 24519299
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis.
Simms KT; Laprise JF; Smith MA; Lew JB; Caruana M; Brisson M; Canfell K
Lancet Public Health; 2016 Dec; 1(2):e66-e75. PubMed ID: 29253419
[TBL] [Abstract][Full Text] [Related]
13. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
McCormack PL; Joura EA
BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
[TBL] [Abstract][Full Text] [Related]
14. Reduced dose human papillomavirus vaccination: an update of the current state-of-the-art.
Toh ZQ; Licciardi PV; Fong J; Garland SM; Tabrizi SN; Russell FM; Mulholland EK
Vaccine; 2015 Sep; 33(39):5042-50. PubMed ID: 26271829
[TBL] [Abstract][Full Text] [Related]
15. Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France.
Riethmuller D; Jacquard AC; Lacau St Guily J; Aubin F; Carcopino X; Pradat P; Dahlab A; Prétet JL
BMC Public Health; 2015 May; 15():453. PubMed ID: 25934423
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs.
Markowitz LE; Drolet M; Perez N; Jit M; Brisson M
Vaccine; 2018 Aug; 36(32 Pt A):4806-4815. PubMed ID: 29802000
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial.
Gilca V; Sauvageau C; Panicker G; De Serres G; Ouakki M; Unger ER
Vaccine; 2018 Nov; 36(46):7017-7024. PubMed ID: 30314913
[TBL] [Abstract][Full Text] [Related]
18. Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine.
Petry KU; Bollaerts K; Bonanni P; Stanley M; Drury R; Joura E; Kjaer SK; Meijer CJLM; Riethmuller D; Soubeyrand B; Van Damme P; Bosch X
Hum Vaccin Immunother; 2018 Jul; 14(7):1800-1806. PubMed ID: 29553886
[TBL] [Abstract][Full Text] [Related]
19. [The 2-dose schedule of HPV vaccines in young adolescents].
Sehnal B; Neumannová N; Driák D; Halaška M; Kotoulová M; Sláma J
Ceska Gynekol; 2015 Jan; 80(1):50-6. PubMed ID: 25723080
[TBL] [Abstract][Full Text] [Related]
20. Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine.
Drolet M; Laprise JF; Boily MC; Franco EL; Brisson M
Int J Cancer; 2014 May; 134(9):2264-8. PubMed ID: 24174175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
